Lennart Holterman - Concepedia

Author

Lennart Holterman

Amsterdam UMC Location University of Amsterdam

Also Known As

L Holterman, L. Holterman, Lennart HOLTERMAN, Lennart Holterman

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location University of Amsterdam Beth Israel Deaconess Medical Center Harvard University Johnson & Johnson (Netherlands)Biomedical Primate Research Centre

About

Lennart Holterman is an author at Amsterdam UMC Location University of Amsterdam specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1.3K
2	Natural Sciences	4	4	107
3	Biochemistry	3	3	126
4	Engineering	1	1	43
5	Allergy	1	1	21

Lennart Holterman

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D Peter Abbink, Angelique A. C. Lemckert, Bonnie A. Ewald, Journal of Virology	2007	503
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity D.M. Roberts, Anjali Nanda, Menzo Havenga, Nature ImmunologyAntiviral ResponseVirologyMedicineViral Genetics	2006	486
Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity Angelique A. C. Lemckert, Shawn M. Sumida, Lennart Holterman, Journal of Virology	2005	156
Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5 Lennart Holterman, Ronald Vogels, Remko van der Vlugt, Journal of Virology Viral ReplicationImmunologyPathologyImmunotherapyHuman Retrovirus	2004	143
Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa Anna R. Thorner, Ronald Vogels, Jorn Kaspers, Journal of Clinical Microbiology VaccinationAntibody TitersViral PersistenceVaccine DevelopmentViral Diagnostics	2006	112
Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells Menzo Havenga, Ronald Vogels, David Zuijdgeest, Journal of General Virology Viral ReplicationViral Polymerase MechanismImmunologyHigh Vector StabilityImmunotherapy	2006	95
Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell Responses Karin Loré, William C. Adams, Menzo Havenga, The Journal of Immunology	2007	91
Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity Angelique A. C. Lemckert, Jos Grimbergen, Shirley Smits, Journal of General Virology VaccinationRad5.sivgag VaccineRad49 VectorViral ReplicationVaccine Development	2006	90
Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against<i>Plasmodium yoelii</i>in Mice Olga Ophorst, Kristina Radošević, Menzo Havenga, Infection and Immunity VaccinationVaccine DevelopmentVaccine TargetMalariaImmunology	2005	73
Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus–adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN William C. Adams, Emily Bond, Menzo Havenga, Journal of General Virology InflammationDermal DcsMolecular VirologyNeurovirologyViral Pathogenesis	2009	65

Page 1